Logo

GSK's Benlysta (belimumab) Receives CHMP's Opinion Recommending its Approval for Active Lupus Nephritis

Share this

GSK's Benlysta (belimumab) Receives CHMP's Opinion Recommending its Approval for Active Lupus Nephritis

Shots:

  • EMA’s CHMP has adopted a positive opinion recommending the use of Benlysta (IV- SC) in combination with background immunosuppressive therapies for the treatment of adult patients with active LN
  • The opinion is based on a P-III BLISS-LN study assessing Benlysta (IV-10 mg/kg) + standard therapy vs PBO in 448 adult patients with active LN for 104wks. The study met its 1EPs i.e. greater number of patients achieved primary efficacy renal response @2yrs. (43% vs 32%) and has achieved all its 2EPs
  • If approved- Benlysta would be the first and only biologic approved for both SLE and LN in the EU. The CHMP opinion follows the recent US FDA’s label expansion to include LN

­ Ref: GSK | Image: GSK

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions